Kalaris Therapeutics (NASDAQ:KLRS – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.06, FiscalAI reports.
Kalaris Therapeutics Trading Up 1.3%
Shares of NASDAQ KLRS opened at $4.79 on Wednesday. The firm has a market capitalization of $110.12 million, a price-to-earnings ratio of -1.14 and a beta of 0.15. Kalaris Therapeutics has a 12-month low of $2.14 and a 12-month high of $11.88. The firm has a 50 day moving average of $6.78 and a 200 day moving average of $7.52.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on KLRS. Morgan Stanley began coverage on shares of Kalaris Therapeutics in a research note on Thursday, April 16th. They issued an “overweight” rating and a $14.00 price target for the company. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research report on Wednesday. Finally, Wall Street Zen upgraded Kalaris Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Kalaris Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $14.00.
Hedge Funds Weigh In On Kalaris Therapeutics
Several institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP purchased a new stake in shares of Kalaris Therapeutics in the fourth quarter valued at $10,972,000. Paradigm Biocapital Advisors LP purchased a new position in shares of Kalaris Therapeutics during the 4th quarter worth about $5,908,000. Siren L.L.C. grew its holdings in Kalaris Therapeutics by 36.9% during the 4th quarter. Siren L.L.C. now owns 435,798 shares of the company’s stock valued at $3,678,000 after purchasing an additional 117,534 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Kalaris Therapeutics in the 4th quarter worth about $3,402,000. Finally, Ikarian Capital LLC bought a new stake in Kalaris Therapeutics in the fourth quarter worth about $3,038,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.
Kalaris Therapeutics Company Profile
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
Recommended Stories
- Five stocks we like better than Kalaris Therapeutics
- Why OpenAI’s IPO Plans Could Be a Massive Win for Microsoft
- A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
Receive News & Ratings for Kalaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
